APIM Therapeutics has already raised more than EUR 23M from public and private sources since 2010. Current major investors in the company include: Sarsia Seed, Trond Mohn Stiftelse, Investinor AS and Birk Venture. The procceeds of the latest financing round are currently used to pursue further clinical development of ATX-101. For more information on potential investments, feel free to contact us.
